OUR MANAGEMENT

Alphora's highly trained and experienced synthetic organic and analytical chemists operate as a single team on each project, to ensure clinical and commercial success. 

 

GEOFF EVANS, P.Eng. MBA |  President 

Geoff Evans obtained his Bachelor of Applied Science in Chemical Engineering from the University of Waterloo in 1987, followed by a Masters of Business Administration from the Schulich School of Business, York University in 1996.

 

Geoff has extensive experience within the pharmaceutical industry, having overseen the safe introduction of over 300 unique reaction processes to plant operations for API's and their intermediates. He has successfully built, staffed and operated laboratory, kilo-laboratory, and plant operations for which FDA approval was successfully obtained.  Since joining Alphora shortly after start-up, Geoff's contributions include establishing Operations and implementing and overseeing the business development and project execution systems.   

 

In addition to his Operational background, Geoff has broad Business Development experience, taking his organizations into new markets through internal growth and acquisitions, and overseeing the introduction of new technologies from conceptualization to market introduction. Geoff is also the inventor of the Aurora Filter®, the preferred filtration standard for Active Pharmaceutical Ingredient manufacturing in scale-up operations.

 

ELENA BEJAN, Ph.D. MBA|
Vice President, Research & Development

Dr. Elena Bejan received her PhD in the field of supramolecular chemistry from Université Paris XI Orsay, France in 1996 and a MBA from Rotman School of Management, University of Toronto in 2018.

 

Following post-doctoral fellowships at University of Houston and University of Ottawa, Elena started her industrial career by joining the Process Research and Development department of Apotex Pharmachem Inc. Elena has extensive experience in the pharmaceutical industry with vast knowledge of innovative and generic drug development, natural products, high-potent compounds and controlled substances. During her career in Process Research and Development at Apotex Pharmachem and Alphora Research, Elena has developed novel synthetic processes for numerous drug candidates including heterocycles, synthetic polypeptides and polymeric amine APIs. Elena has led multiple stages of development and manufacture of several APIs successfully launched to market. Elena is the author of over 30 scientific publications and patents.

 

Since joining Alphora, Elena’s contributions include leading a result-driven, innovative team focused on API technology development programs from early development stages to cGMP manufacture. In her current role Elena is also responsible for managing Clients partnerships/relationships and expanding Alphora’s supply chain network. Elena’s present responsibilities into strategic thinking and corporative decision making are based on in-depth understanding of business and leadership fundamentals, strategic management and marketing techniques. In addition to leading R&D Scientists and API programs, Elena is providing leadership throughout the organization through the power of team building, mentoring and managing change in a fast moving, innovative and highly complex environment.

 

Davinder Singh, B.Sc, B.A, Pharm. Tech., MBA |
Vice President, Operations

Davinder Singh has an educational background in Life Sciences, Business, Economics and Psychology. He obtained his Bachelor of Science in Chemistry/Biology and Psychology from York University, a Bachelor of Arts in Economics from Punjab University, and  Industrial Pharmaceutical Technology designation from Seneca College and York University. He completed an Executive MBA from University of Guelph in 2018.

 

Mr. Singh has extensive experience in the Pharmaceutical industry in starting off new facilities, expanding existing operations, building strong and cohesive cross-functional teams to enhance quality and efficiency. He directs engineering teams in seeking the best possible equipment, validating equipment and processes, and completing technology transfers. He has lead numerous successful regulatory inspections and received approvals from Health Canada, FDA, and EU compliance.

 

Further to his business operations experience, Mr. Singh possesses a strong business acumen in acquisitions and growth, and excels at client service by supporting R&D and business development initiatives.

 

Kevin Rosenthal, B.Sc. |

Business Head, Drug Product Operations

Kevin Rosenthal received his B.Sc. in BioChemistry from San Diego State University in 1996, and completed his Leadership and Management Program at University of California San Diego in 2006. Mr. Rosenthal has over 21 years of operations and leadership experience in the pharmaceutical industry.  He’s been instrumental in the design and commissioning of multiple CDMO facilities with proven expertise in GMP quality systems and IND enabling strategies covering a wide range of dosage forms. Kevin has direct experience in high potent and oral dosage technologies with a focus on early stage development. 

 

Kevin’s has also been directly responsible for several business initiatives to build and develop manufacturing teams from inception to full GMP operation. Further to Kevin’s operations and leadership experience, he has a strong business development background. He’s established several multi-company relationships to provide comprehensive service offerings to clients, enabling expedited CMC development from early stage through delivery of clinical supplies.

 

JANETHE HUBERT, B.Sc. |
Director, Analytical Services

Janethe Hubert received her Bachelor of Science in Applied Chemistry and Biology (Honours) from Ryerson Polytechnical University in 1996 and subsequently joined Torcan Chemical in 1997. She held various positions in analytical research and development, quality control, stability and analytical method validation. She moved to the position of Analytical Team Leader and R&D Analytical Manager throughout her 11 years tenure at Torcan. In 2008 she joined Alphora Research as Analytical Services Team Leader and became Manager of Analytical Services in 2013.

 

Ms. Janethe Hubert has been actively involved in the development and commercialization of a large number of active pharmaceutical ingredients.

SCIENTIFIC ADVISORY BOARD

 

BORIS GORIN, Ph.D. |
Senior Scientific Advisor 

Dr. Boris Gorin, a native of Ukraine, obtained his Master of Science, Magna Cum Laude in chemistry, followed by a Ph.D. in synthetic organic chemistry from Moscow State University for his studies in the synthesis of heterocyclic compounds. Boris furthered his academic studies in Canada in the field of medicinal chemistry working with Dr. Greg Thatcher at Queens University, Kingston, Ontario from 1994-1996.

Boris has over 30 years of experience in synthetic organic chemistry and process development for the pharmaceutical industry. He started his industrial experience at the Institute for Physiologically Active Compounds, with the Russian Academy of Sciences, where he headed the drug design and discovery team. This was followed by his appointment as a Senior Research Chemist with Raylo Chemicals, in Edmonton, Alberta in 1996 where he worked on developing processes for scale-up manufacture of pharmaceutical actives. In 2004 Boris joined Alphora Research Inc. where he headed process R&D team in progressive roles from R&D manager to Vice President, R&D. He was highly instrumental in bringing Alphora Research Inc. from a small start-up to a recognized CRO/CMO organization. From 2016 to 2018 Boris worked as a Director, Research and Technology for Apotex Pharmachem Inc. leading a team focused on developing and implementation of innovative technologies pertaining to API manufacture. He re-joined Eurofins Alphora in January 2018 in a role of a Senior Scientific Advisor.

 

During his career, Boris has developed new synthetic processes for over one hundred new drug candidates, including various classes of natural products, heterocycles and phosphoroorganic compounds. Of these, several APIs were successfully launched to the pharmaceutical market. He was also successful in introduction of new technologies such as High-Throughput-Screening, Continuous Flow Processes, Process Analytical Technology, and others to API process development and optimization. Boris is the author of over 50 patents and scientific publications.

 

 

MARK LAUTENS, Ph.D. |
Research Advisor Officer, Order of Canada 
J.B. Jones Distinguished Professor
AstraZeneca Endowed Chair of Organic Synthesis

Mark Lautens was born in Hamilton and attended the University of Guelph where he worked with Gordon Lange.  He completed his Ph.D. in 1985 with Barry M. Trost at the University of Wisconsin-Madison then conducted post-doctoral studies with David A. Evans at Harvard University.  He joined the faculty at the University of Toronto in 1987 and is currently University Professor, J.B. Jones Distinguished Professor and AstraZeneca Endowed Chair of Organic Synthesis.  From 2001-2013 he was an NSERC/Merck Frosst Industrial Research Chair.

 

Among his awards are the E.W.R. Steacie Fellowship, KIllam Fellowship, CIC Medal, A.P. Sloan Fellow, A.C. Cope Award, Fellowship in the Royal Society of Canada, Lemieux and Bader Awards from the CSC, Alexander von Humboldt Awardee and Pedler Award from the Royal Society of Chemistry (UK).  Most recently he was invested as Officer of the Order of Canada.  His alma mater has recently honoured him with Doctor of Science, honoris, cause.  His research areas are in discovery and applications of novel catalytic reactions and strategies for the synthesis of bioactive molecules of interest to the pharmaceutical industry.

 

PRESTON C. CONRAD, Ph.D. |
Research Advisor

Dr. Preston C. Conrad received his Ph.D. from Purdue University in Organic Chemistry (1980) and subsequently went on to a Postdoctoral Research position (1981) at the University of Wisconsin-Madison. After joining Eli Lilly and Company, Preston enjoyed a rich and fulfilling career preceding recent retirement from Lilly in March of 2016.

 

While at Lilly for 34 years, Preston advanced on the scientific ladder to the position of Research Advisor. Over this same 34 year period, successful experiences and expertise were achieved in the areas of Chemical Process Research and Development, Project Management, and Technical Services / Manufacturing Sciences. Specific areas of experience and expertise were developed with regard to chemical process development, late stage process optimization for syntheses of APIs, process validation, and technical transfer to internal and external nodes. Direct responsibility for numerous manufacturing processes endowed Dr. Conrad with a deep understanding and technical knowledge of process installations at multi-ton per year scale, scale-up, and routine operation of multi-step API manufacturing processes. The end result achieved was improved throughput, lower costs, capable impurity control strategies, and in control production processes. Outsourcing of commercial manufacturing processes also lead to significant experience and expertise for evaluations, due diligences, technical transfers, and process validations to / or at third party (CMO) organizations. In addition he served in a leadership role for the manufacturability reviews of chemical process for new and existing APIs. Dr. Conrad received the top award for scientific achievement at Eli Lilly and Company three times.

 

He joined Alphora Research as a Research Advisor focused on providing scientific support to the research & development team in process chemistry, project troubleshooting, process scale-up challenges, process validation projects, and chemical development processes.